News | August 12, 2021
Mangalam Drugs signs tech transfer agreement with Nigerian pharma company
Anti-malaria API facility will be operational in 15-18 months
Anti-malaria API facility will be operational in 15-18 months
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
Acquisition of A&C expands Aceto’s Western manufacturing footprint
Partnership with Duopharma Biotech covers human insulin, insulin glargine and insulin aspart, supporting diabetes care and medicine security in Malaysia
The incubator anchored at the company's global headquarters in Raleighla launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm
As per the company’s Restated H1 2025 Financials, its continuing business delivered CORE EBITDA of CHF 922 million, representing a margin of 30.4%
The company reported consolidated revenue of Rs. 172.9 crore and EBITDA of Rs 25.9 crore in FY26
The company said the safety profile remained consistent with earlier studies and was considered manageable
The company plans an aggressive partnering push, with 62 pre-scheduled meetings over four days, focused on out-licensing, co-development, and strategic collaborations with global pharmaceutical and biotech players
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
